Related Experiment Video
Updated: Jan 28, 2026
Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
Published on: August 25, 2017
PI3K/Akt-Nrf2 and Anti-Inflammation Effect of Macrolides in Chronic Obstructive Pulmonary Disease
Xuejiao Sun1, Lin Chen1, Zhiyi He2
1Department of Respiratory and Critical Care Medicine, Liuzhou General Hospital, Liuzhou, Guangxi 545006, China.
Background:
Chronic Obstructive Pulmonary Disease (COPD) is a systematic inflammatory disease, and smoking is an important risk factor for COPD. Macrolide can reduce COPD inflammation. However, the inflammatory mechanism of COPD remains unclear and the anti-inflammatory mechanism of Macrolide is complex and not exactly known.
Methods:
We read and analysed thirty-eight articles, including original articles and reviews.
Results:
The expression of Nrf2 was lower in COPD patients and might have a protective role against apoptosis caused by CSE-induced oxidative stress. Nrf2 may play an important role in COPD inflammation. Nrf2 is a key factor in downstream of PI3K/Akt and is involved in the regulation of oxidative stress and inflammatory response. Therefore, PI3K/Akt pathway may play an important role in the activation of Nrf2 and COPD inflammation. Macrolide reduces lung and systemic inflammation of COPD by regulating PI3K/Akt pathway.
Conclusion:
This review indicates that PI3K/Ak-Nrf2 may play an important role in COPD inflammation and macrolides may reduce lung and systemic inflammation of COPD by regulating PI3K/Akt-Nrf2 pathway. However, many crucial and essential questions remain to be answered. Further understanding of the mechanisms of macrolide efficacy and PI3K/Akt-Nrf2-mediated inflammatory responses may provide a new clue for exploring COPD treatment in the future.
Insights
Macrolides may reduce Chronic Obstructive Pulmonary Disease (COPD) inflammation by targeting the PI3K/Akt-Nrf2 pathway. Further research into this mechanism could reveal new COPD treatment strategies.
Area of Science:
- Pulmonary Medicine
- Molecular Biology
- Pharmacology
Background:
- Chronic Obstructive Pulmonary Disease (COPD) is a systemic inflammatory condition with smoking as a major risk factor.
- While macrolides show anti-inflammatory effects in COPD, the precise mechanisms remain unclear.
- Understanding COPD inflammation and macrolide action is crucial for developing effective treatments.
Purpose of the Study:
- To elucidate the role of the PI3K/Akt-Nrf2 pathway in COPD inflammation.
- To explore the anti-inflammatory mechanisms of macrolides in COPD.
- To identify potential therapeutic targets for COPD treatment.
Main Methods:
- Systematic review and analysis of 38 relevant articles, including original research and reviews.
- Examination of molecular pathways involved in COPD pathogenesis and inflammation.
- Analysis of the impact of macrolides on inflammatory markers and signaling pathways.
Main Results:
- Reduced Nrf2 expression observed in COPD patients, suggesting a protective role against apoptosis and oxidative stress.
- The PI3K/Akt pathway is identified as a key regulator of Nrf2 activation, oxidative stress, and inflammation in COPD.
- Macrolides demonstrate an ability to mitigate lung and systemic inflammation in COPD by modulating the PI3K/Akt pathway.
Conclusions:
- The PI3K/Akt-Nrf2 pathway is implicated in COPD inflammation, with macrolides potentially exerting therapeutic effects via this route.
- Further investigation is needed to fully understand macrolide efficacy and the PI3K/Akt-Nrf2 pathway's role in inflammation.
- Unraveling these mechanisms may offer novel therapeutic avenues for COPD management.
Related Concept Videos
01:22Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
01:29Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
01:30Chronic Obstructive Pulmonary Disease-V: Nursing Management
Assessment
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD: